



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 75416

Title: Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05130847

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2022-02-05

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-07 16:27

Reviewer performed review: 2022-02-15 15:49

Review time: 7 Days and 23 Hours

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

This manuscript retrospectively analyzed the association between neutrophil-to-lymphocyte ratio and irAEs (hypothyroidism) in tumor nivolumab treatment. The results showed that low NLR at the treatment initiation increases the incidence of immune-related hypothyroidism and the persistence of low NLR levels may be a risk factor for the early development of hypothyroidism. Despite the limitations of retrospective studies as pointed out in this article, the findings of this article have certain experimental basis for future prospective clinical trials.



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 75416

Title: Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 01213078

Position: Editorial Board

Academic degree: PhD

Professional title: Professor, Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2022-02-05

Reviewer chosen by: Jia-Qi Zhu

Reviewer accepted review: 2022-04-17 08:49

Reviewer performed review: 2022-04-22 08:04

Review time: 4 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

This manuscript evaluated the effect of NLR fluctuations during nivolumab treatment on the incidence and onset period of hypothyroid. Results showed patients with hypothyroidism had a significantly lower NLR at the treatment initiation, and the incidence of hypothyroidism was higher among those with NLR <5. Patients with persistently low NLR (<3.5) developed hypothyroidism earlier. And concluded that low NLR at the treatment initiation increases the incidence of treatment-induced hypothyroidism and its persistence may be a risk factor for the early onset of hypothyroidism. These findings provide an easy available parameter to predict the development of hypothyroidism during nivolumab treatment. Limitations included: The reason for patient to discontinue nivolumab and whether it was related to hypothyroidism need to be discussed in the manuscript.



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 75416

Title: Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05194375

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2022-02-05

Reviewer chosen by: Jia-Qi Zhu

Reviewer accepted review: 2022-04-17 01:54

Reviewer performed review: 2022-04-24 02:50

Review time: 7 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

This article mainly investigates the effect of NLR fluctuation on the incidence and onset period of hypothyroidism during nivolumab treatment. The manuscript is well written, however, there are still some concerns about this review. 1. In part "INTRODUCTION", I suggest that the introduction about nivolumab should be more detailed. 2. In this study, the follow-up period is up to the 12th administration, is the interval between two consecutive treatments the same? How long? 3. The included patients discontinued treatment after receiving <6, 6-11, or ≥12 nivolumab administrations. Why are patients discontinued nivolumab treatment? Are there some relevant criteria or indications? 4. In part "Statistics", are continuous variables tested for normality? I think it is necessary to declare. 5. In Table1, it is normative that the data of the same variable keep the same decimal places (eg. P value). Additionally, the layout of Table1 should be improved, for example, "median" and "(min-max)" should be inputted in one table cell.